NCT02607904 - An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

May 27, 2019

Study Completion Date

May 27, 2019

Conditions

Epilepsy

Interventions

DRUG

GWP42003-P

Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Trial Locations (5)

Unknown

SEIN - Epilepsy Institute in the Netherlands Foundation, Zwolle

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Ruber Internacional, Madrid

Hospital Universitario Virgen del Rocio, Seville

Sahlgrenska University Hospital, Gothenburg